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Background: Chronic pressure overload induces cardiac hypertrophy and leads to left ventricular (LV) dysfunction. Thrombomodulin (TM), 
traditionally known as an anticoagulant protein, was found to have direct cellular effects recently. We found significant TM expression in 
cardiomyocytes (CM) during cardiac hypertrophy. The purpose of the study is to investigate the physiological effect of TM on CM. 
Methods and Results: Data were expressed as mean±SE. Cultured CMs (H9c2 cell line) were pretreated with recombinant TM protein or saline 
and apoptosis was induced by adding doxorubicin (DOX, 1μM). Quantification of apoptotic DNA fragmentation with the Cell Death Detection ELISA 
kit showed that TM reduced CM apoptosis (saline vs 10 vs 30 vs 50 ng/mL TM, apoptosis ratio: 1 vs 0.67±0.03 vs 0.64±0.01 vs 0.58±0.01, 
p<0.01). Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay also showed that TM reduced the number of TUNEL-
positive CM (saline vs 10 vs 30 vs 50 ng/mL TM, apoptotic cell number: 33±8 vs 19±10 vs 14±5 vs 10±5, p<0.01). In DOX-treated CM, Western blot 
showed that TM-pretreated cells had an increased Bcl-2/Bax ratio compared with the saline-pretreated cells (1.73±0.17 vs 0.64±0.02, p<0.05). The 
anti-apoptotic effect of TM was blocked by ERK1/2 inhibitor, U0126 and Akt inhibitor, LY 294002. Western blot showed that TM induced ERK1/2 and 
Akt phosphorylation in CM. Recombinant TM protein (145 μg/kg/day) or saline was administered from the subcutaneously implanted mini-pumps 
for 6 wk after transverse aortic constriction (TAC) in mice. The LV ejection fraction in TM-treated mice was significantly higher than the saline-treated 
mice at 6 wk (54.2±2.0 vs 47.9±5.7%, p<0.05) and 12 wk (53.1±2.6 vs 48.6±5.2%, p<0.05) after TAC. In TM-treated mouse hearts, less apoptotic 
CM was noted in TUNEL assay at 1 wk after TAC (0.43±0.10 vs 8.43±0.51/high power field, p<0.01). Western blot showed a higher Bcl-2/Bax ratio in 
TM- than saline-treated mouse hearts (1.75±0.38 vs 0.76±0.09, p<0.05). 
Conclusion: TM treatment decreases CM apoptosis and improves LV contractile dysfunction. The results indicate that TM has a therapeutic 
potential against heart failure.
